Rare Disease Consulting
Alkemi partners with stakeholders who seek to advance rare disease therapeutics, disease outcomes and patient access.
Rare Disease Expertise
Alkemi collaborates with life science companies, patient advocates, guideline groups, medical thought-leaders, and payers to develop the appropriate evidence and insights required to advance rare disease outcomes. Our publications include research on unmet needs in rare disease therapeutic areas, including oncology and immunology.
Our Rare Disease Specialization
Strategic Evidence Generation
Why is it important to be strategic when it comes to evidence generation? Designing and executing studies is resource intensive. Additionally, patient lives and well-being are at stake, so time is at a premium.
Alkemi partners with clients to create a strategy that is efficient, targeted and informed with decision-maker insights. Our evidence generation strategies often encompass rare disease, real world evidence, health economics and outcomes research to achieve market access. Our goal – like yours – is to ensure novel treatments reach the patients in greatest need.
Our team of experienced researchers and market access consultants specialize in the following: